Browsing Tag
American Society of Clinical Oncology
9 posts
Corbus Pharmaceuticals (NASDAQ: CRBP) lands FDA clearance for TEMPO-1 as CRB-701 enters Phase 3
CRB-701 delivered a 42.9% ORR in 2L OPSCC. Corbus Pharmaceuticals must now reproduce it in a 250-patient TEMPO-1 trial that starts enrolling in September.
Avacta targets late-2026 AVA6103 data as AVCT shifts from funding risk to clinical proof
Avacta Group has outlined a catalyst-heavy second half of 2026, with new AVA6000 data, the first AVA6103 clinical results and potential partnering decisions set to test the commercial value of its tumour-activated oncology platform.
OncoSil Medical (OSL:ASX) has pancreatic cancer data momentum, but investors now need adoption proof
OSL has TRIPP-FFX data, TGA approval and FDA pathway momentum. The bigger test is whether OncoSil can turn evidence into adoption.
Legend Biotech soars 42% on ASCO data as CAR-T momentum extends from blood cancers toward solid tumors
Legend Biotech soared 42% on ASCO data: a survival readout for myeloma CAR-T CARVYKTI plus early solid-tumor results for LB2102. Big ramp, but still loss-making.
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.
GT Medical Technologies’ GammaTile Phase 3 data strengthens case for surgery-time radiation in brain metastases
GammaTile’s Phase 3 data challenges delayed brain radiation after surgery. The bigger question is whether hospitals will change workflows.
Bristol Myers Squibb myeloma drug doubles progression-free survival in pivotal SUCCESSOR-2 trial
Bristol Myers Squibb's mezigdomide doubled myeloma progression-free survival to 18 months and cut progression or death risk 52% in Phase 3, key to its patent-cliff plan.
Nuvalent (NUVL) brings full ALKOVE-1 dataset to ASCO 2026 oral session weeks after neladalkib FDA filing
Nuvalent (NUVL) brings pivotal ALKOVE-1 neladalkib data to ASCO 2026. Here's what the oral session means for its dual NDA strategy and ALK lung cancer treatment.
INOVIQ (ASX: IIQ) soars on breakthrough ovarian cancer test data at ASCO 2025
INOVIQ Ltd (ASX: IIQ) stock surged 47.73% after ASCO 2025 data showed 77% sensitivity, 99.6% specificity in ovarian cancer screening. Explore what's next for EXO-OC.